Ignite Creation Date:
2025-12-25 @ 2:38 AM
Ignite Modification Date:
2026-04-21 @ 9:03 AM
Study NCT ID:
NCT00125034
Status:
COMPLETED
Last Update Posted:
2014-08-07
First Post:
2005-07-28
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)
Sponsor:
Merck KGaA, Darmstadt, Germany
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
EMR 62202-047
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None